Robot-assisted radical nephroureterectomy using the KangDuo Surgical Robot-01 System versus the da Vinci System: a multicenter prospective randomized controlled trial.
Zhongyuan Zhang, Zhenyu Li, Weifeng Xu, Xuan Wang, Shengcai Zhu, Jie Dong, Xiaojun Tian, Wei Zuo, Qi Tang, Zhihua Li, Kunlin Yang, Xiaoqiang Xue, Yingjie Li, Hongxian Zhang, Qiming Zhang, Silu Chen, Zhaoheng Jin, Xuesong Li, Zhigang Ji, Lulin Ma, Ming Liu
{"title":"Robot-assisted radical nephroureterectomy using the KangDuo Surgical Robot-01 System versus the da Vinci System: a multicenter prospective randomized controlled trial.","authors":"Zhongyuan Zhang, Zhenyu Li, Weifeng Xu, Xuan Wang, Shengcai Zhu, Jie Dong, Xiaojun Tian, Wei Zuo, Qi Tang, Zhihua Li, Kunlin Yang, Xiaoqiang Xue, Yingjie Li, Hongxian Zhang, Qiming Zhang, Silu Chen, Zhaoheng Jin, Xuesong Li, Zhigang Ji, Lulin Ma, Ming Liu","doi":"10.1590/S1677-5538.IBJU.2024.0230","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>We aim to compare the safety and effectiveness of the KangDuo (KD)-Surgical Robot-01 (KD-SR-01) system and the da Vinci (DV) system for robot-assisted radical nephroureterectomy (RARNU).</p><p><strong>Materials and methods: </strong>This multicenter prospective randomized controlled trial was conducted between March 2022 and September 2023. Group 1 included 29 patients undergoing KD-RARNU. Group 2 included 29 patients undergoing DV-RARNU. Patient demographic and clinical characteristics, perioperative data, and follow-up outcomes were collected prospectively and compared between the two groups.</p><p><strong>Results: </strong>There were no significant differences in patient baseline demographic and preoperative characteristics between the two groups. The success rates in both groups were 100% without conversion to open or laparoscopic surgery or positive surgical margins. No significant difference was observed in docking time [242 (120-951) s vs 253 (62-498) s, P = 0.780], console time [137 (55-290) min vs 105 (62-220) min, P = 0.114], operative time [207 (121-460) min vs 185 (96-305) min, P = 0.091], EBL [50 (10-600) mL vs 50 (10-700) mL, P = 0.507], National Aeronautics and Space Administration Task Load Index scores, and postoperative serum creatinine levels between the two groups. None of the patients showed evidence of distant metastasis, local recurrence, or equipment-related adverse events during the four-week follow-up. One (3.4%) patient in Group 2 experienced postoperative enterovaginal and enterovesical fistulas (Clavien-Dindo grade III).</p><p><strong>Conclusions: </strong>The KD-SR-01 system is safe and effective for RARNU compared to the DV Si or Xi system. Further randomized controlled studies with larger sample sizes and longer durations are required.</p>","PeriodicalId":49283,"journal":{"name":"International Braz J Urol","volume":"50 ","pages":"727-736"},"PeriodicalIF":3.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554279/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Braz J Urol","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1590/S1677-5538.IBJU.2024.0230","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: We aim to compare the safety and effectiveness of the KangDuo (KD)-Surgical Robot-01 (KD-SR-01) system and the da Vinci (DV) system for robot-assisted radical nephroureterectomy (RARNU).
Materials and methods: This multicenter prospective randomized controlled trial was conducted between March 2022 and September 2023. Group 1 included 29 patients undergoing KD-RARNU. Group 2 included 29 patients undergoing DV-RARNU. Patient demographic and clinical characteristics, perioperative data, and follow-up outcomes were collected prospectively and compared between the two groups.
Results: There were no significant differences in patient baseline demographic and preoperative characteristics between the two groups. The success rates in both groups were 100% without conversion to open or laparoscopic surgery or positive surgical margins. No significant difference was observed in docking time [242 (120-951) s vs 253 (62-498) s, P = 0.780], console time [137 (55-290) min vs 105 (62-220) min, P = 0.114], operative time [207 (121-460) min vs 185 (96-305) min, P = 0.091], EBL [50 (10-600) mL vs 50 (10-700) mL, P = 0.507], National Aeronautics and Space Administration Task Load Index scores, and postoperative serum creatinine levels between the two groups. None of the patients showed evidence of distant metastasis, local recurrence, or equipment-related adverse events during the four-week follow-up. One (3.4%) patient in Group 2 experienced postoperative enterovaginal and enterovesical fistulas (Clavien-Dindo grade III).
Conclusions: The KD-SR-01 system is safe and effective for RARNU compared to the DV Si or Xi system. Further randomized controlled studies with larger sample sizes and longer durations are required.
简介我们旨在比较康多(KD)-手术机器人-01(KD-SR-01)系统和达芬奇(DV)系统用于机器人辅助根治性肾切除术(RARNU)的安全性和有效性:这项多中心前瞻性随机对照试验于2022年3月至2023年9月期间进行。第一组包括 29 名接受 KD-RARNU 手术的患者。第2组包括29名接受DV-RARNU治疗的患者。对两组患者的人口统计学特征、临床特征、围手术期数据和随访结果进行了前瞻性收集和比较:结果:两组患者的基本人口统计学特征和术前特征无明显差异。两组手术的成功率均为100%,没有出现转为开腹或腹腔镜手术或手术切缘阳性的情况。对接时间[242(120-951)秒 vs 253(62-498)秒,P = 0.780]、控制台时间[137(55-290)分钟 vs 105(62-220)分钟,P = 0.114]、手术时间[207(121-460)分钟 vs 185(96-305)分钟,P = 0.091]、EBL[50 (10-600) mL vs 50 (10-700) mL,P = 0.507]、美国国家航空航天局任务负荷指数评分以及术后血清肌酐水平在两组之间存在差异。在四周的随访中,没有一名患者出现远处转移、局部复发或与设备相关的不良事件。第二组中有一名(3.4%)患者术后出现肠瘘和肠道瘘(Clavien-Dindo III级):结论:与 DV Si 或 Xi 系统相比,KD-SR-01 系统对 RARNU 安全有效。需要进一步开展样本量更大、持续时间更长的随机对照研究。